Oxidative stress and antioxidant therapy in cystic fibrosis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 5, 2012, Pages 690-713

  Galli, Francesco ^a   Battistoni, Andrea ^b   Gambari, Roberto ^c   Pompella, Alfonso ^d   Bragonzi, Alessandra ^e   Pilolli, Francesca ^a   Iuliano, Luigi ^f   Piroddi, Marta ^a   Dechecchi, Maria Cristina ^g   Cabrini, Giulio ^g  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Antioxidant; Cystic fibrosis; Glutathione; Inflammation; Oxidative stress; Reactive oxygen species

Indexed keywords

ALANINE; ALPHA TOCOPHEROL; ANTIOXIDANT; CAROTENOID; COPPER; FATTY ACID; GLUTAMINE; GLUTATHIONE; NITRIC OXIDE; NITROGEN; POLYUNSATURATED FATTY ACID; PYRUVATE SODIUM; QUERCETIN; REACTIVE OXYGEN METABOLITE; SELENIUM; SURFACTANT; UBIDECARENONE; ZINC;

CLINICAL TRIAL; CYSTIC FIBROSIS; DETOXIFICATION; GLUTATHIONE METABOLISM; HOMEOSTASIS; HUMAN; LUNG ALVEOLUS EPITHELIUM; MALNUTRITION; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANTIOXIDANTS; CYSTIC FIBROSIS; HUMANS; INFLAMMATION; OXIDATIVE STRESS;

EID: 84858294319     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.12.012     Document Type: Review

References (299)

1. O'Sullivan B.P., Freedman S.D. Cystic fibrosis. Lancet 2009, 373:1891-1904.
2. Linsdell P., Hanrahan J.W. Glutathione permeability of CFTR. Am. J. Physiol. 1998, 275:C323-C326.
3. Gao L., Kim K.J., Yankaskas J.R., Forman H.J. Abnormal glutathione transport in cystic fibrosis airway epithelia. Am. J. Physiol. 1999, 277:L113-L118.
4. Rowntree R.K., Harris A. The phenotypic consequences of CFTR mutations. Ann. Hum. Genet. 2003, 67:471-485.
5. Back E.I., Frindt C., Nohr D., Frank J., Ziebach R., Stern M., Ranke M., Biesalski H.K. Antioxidant deficiency in cystic fibrosis: when is the right time to take action?. Am. J. Clin. Nutr. 2004, 80:374-384.
6. Wood L.G., Fitzgerald D.A., Lee A.K., Garg M.L. Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. Am. J. Clin. Nutr. 2003, 77:150-159.
7. Iuliano L., Monticolo R., Straface G., Zullo S., Galli F., Boaz M., Quattrucci S. Association of cholesterol oxidation and abnormalities in fatty acid metabolism in cystic fibrosis. Am. J. Clin. Nutr. 2009, 90:477-484.
8. Libetta C., Sepe V., Esposito P., Galli F., Dal Canton A. Oxidative stress and inflammation: implications in uremia and hemodialysis. Clin. Biochem. 2011, 44:1189-1198.
9. Bartosz G. Reactive oxygen species: destroyers or messengers?. Biochem. Pharmacol. 2009, 77:1303-1315.
10. Ntimbane T., Comte B., Mailhot G., Berthiaume Y., Poitout V., Prentki M., Rabasa-Lhoret R., Levy E. Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress. Clin. Biochem. 2009, 30:153-177.
11. van der Vliet A., Eiserich J.P., Marelich G.P., Halliwell B., Cross C.E. Oxidative stress in cystic fibrosis: does it occur and does it matter?. Adv. Pharmacol. 1997, 38:491-513.
12. Cantin A.M., White T.B., Cross C.E., Forman H.J., Sokol R.J., Borowitz D. Antioxidants in cystic fibrosis. Conclusions from the CF antioxidant workshop, Bethesda, Maryland. Free Radic. Biol. Med. 2007, 42:15-31.
13. McGrath L.T., Mallon P., Dowey L., Silke B., McClean E., McDonnell M., Devine A., Copeland S., Elborn S. Oxidative stress during acute respiratory exacerbations in cystic fibrosis. Thorax 1999, 54:518-523.
14. Thomson E., Brennan S., Senthilmohan R., Gangell C.L., Chapman A.L., Sly P.D., Kettle A.J., Balding E., Berry L.J., Carlin J.B., Carzino R., de Klerk N., Douglas T., Foo C., Garratt L.W., Hall G.L., Harrison J., Kicic A., Laing I.A., Logie K.M., Massie J., Mott L.S., Murray C., Parsons F., Pillarisetti N., Poreddy S.R., Ranganathan S.C., Robertson C.F., Robins-Browne R., Robinson P.J., Skoric B., Stick S.M., Sutanto E.N., Williamson E. Identifying peroxidases and their oxidants in the early pathology of cystic fibrosis. Free Radic. Biol. Med. 2010, 49:1354-1360.
15. Range S.P., Dunster C., Knox A.J., Kelly F.J. Treatment of pulmonary exacerbations of cystic fibrosis leads to improved antioxidant status. Eur. Respir. J. 1999, 13:560-564.
16. Coppo L., Ghezzi P. Thiol regulation of pro-inflammatory cytokines and innate immunity: protein S-thiolation as a novel molecular mechanism. Biochem. Soc. Trans. 2011, 39:1268-1272.
17. Verhaeghe C., Remouchamps C., Hennuy B., Vanderplasschen A., Chariot A., Tabruyn S.P., Oury C., Bours V. Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem. Pharmacol. 2007, 73:1982-1994.
18. Bonfield T.L., Panuska J.R., Konstan M.W., Hilliard K.A., Hilliard J.B., Ghnaim H., Berger M. Inflammatory cytokines in cystic fibrosis lungs. Am. J. Respir. Crit. Care Med. 1995, 152:2111-2118.
19. Noah T.L., Black H.R., Cheng P.W., Wood R.E., Leigh M.W. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. J. Infect. Dis. 1997, 175:638-647.
20. Welsh M.J., Ramsey B.W., Accurso F.J., Cutting G.R. Cystic Fibrosis 2001, McGraw-Hill, New York.
21. Khan T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., Riches D.W. Early pulmonary inflammation in infants with cystic fibrosis. Am. J. Respir. Crit. Care Med. 1995, 151:1075-1082.
22. Ratjen F.A. Cystic fibrosis: pathogenesis and future treatment strategies. Respir. Care 2009, 54:595-605.
23. Jacquot J., Tabary O., Le Rouzic P., Clement A. Airway epithelial cell inflammatory signalling in cystic fibrosis. Int. J. Biochem. Cell Biol. 2008, 40:1703-1715.
24. Greene C.M., Branagan P., McElvaney N.G. Toll-like receptors as therapeutic targets in cystic fibrosis. Expert Opin. Ther. Targets 2008, 12:1481-1495.
25. Rottner M., Freyssinet J.M., Martinez M.C. Mechanisms of the noxious inflammatory cycle in cystic fibrosis. Respir. Res. 2009, 10:23.
26. Cabrini G., Bezzerri V., Mancini I., Nicolis E., Dechecchi M.C., Tamanini A., Lampronti I., Piccagli L., Bianchi N., Borgatti M., Gambari R. Targeting transcription factor activity as a strategy to inhibit pro-inflammatory genes involved in cystic fibrosis: decoy oligonucleotides and low-molecular weight compounds. Curr. Med. Chem. 2010, 17:4392-4404.
27. Greene C.M., McElvaney N.G. Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery. Br. J. Pharmacol. 2009, 158:1048-1058.
28. Cantin A.M. Potential for antioxidant therapy of cystic fibrosis. Curr. Opin. Pulm. Med. 2004, 10:531-536.
29. Chmiel J.F., Konstan M.W. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin. Chest Med. 2007, 28:331-346.
30. Nichols D.P., Konstan M.W., Chmiel J.F. Anti-inflammatory therapies for cystic fibrosis-related lung disease. Clin. Rev. Allergy Immunol. 2008, 35:135-153.
31. Kettle A.J., Chan T., Osberg I., Senthilmohan R., Chapman A.L., Mocatta T.J., Wagener J.S. Myeloperoxidase and protein oxidation in the airways of young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2004, 170:1317-1323.
32. Fischer H. Mechanisms and function of DUOX in epithelia of the lung. Antioxid. Redox Signal. 2009, 11:2453-2465.
33. Rada B., Leto T.L. Oxidative innate immune defenses by Nox/Duox family NADPH oxidases. Contrib. Microbiol. 2008, 15:164-187.
34. Moskwa P., Lorentzen D., Excoffon K.J., Zabner J., McCray P.B., Nauseef W.M., Dupuy C., Banfi B. A novel host defense system of airways is defective in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2007, 175:174-183.
35. Lorentzen D., Durairaj L., Pezzulo A.A., Nakano Y., Launspach J., Stoltz D.A., Zamba G., McCray P.B., Zabner J., Welsh M.J., Nauseef W.M., Banfi B. Concentration of the antibacterial precursor thiocyanate in cystic fibrosis airway secretions. Free Radic. Biol. Med. 2011, 50:1144-1150.
36. Xu Y., Szep S., Lu Z. The antioxidant role of thiocyanate in the pathogenesis of cystic fibrosis and other inflammation-related diseases. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20515-20519.
37. Rogan M.P., Taggart C.C., Greene C.M., Murphy P.G., O'Neill S.J., McElvaney N.G. Loss of microbicidal activity and increased formation of biofilm due to decreased lactoferrin activity in patients with cystic fibrosis. J. Infect. Dis. 2004, 190:1245-1253.
38. Halliwell B., Guttridge J.M. Free Radicals in Biology and Medicine 2007, Oxford University Press, New York. Fourth edition.
39. Rada B., Lekstrom K., Damian S., Dupuy C., Leto T.L. The Pseudomonas toxin pyocyanin inhibits the dual oxidase-based antimicrobial system as it imposes oxidative stress on airway epithelial cells. J. Immunol. 2008, 181:4883-4893.
40. Schwarzer C., Illek B., Suh J.H., Remington S.J., Fischer H., Machen T.E. Organelle redox of CF and CFTR-corrected airway epithelia. Free Radic. Biol. Med. 2007, 43:300-316.
41. Roum J.H., Buhl R., McElvaney N.G., Borok Z., Crystal R.G. Systemic deficiency of glutathione in cystic fibrosis. J. Appl. Physiol. 1993, 75:2419-2424.
42. Hudson V.M. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic. Biol. Med. 2001, 30:1440-1461.
43. Barnes P.J., Dweik R.A., Gelb A.F., Gibson P.G., George S.C., Grasemann H., Pavord I.D., Ratjen F., Silkoff P.E., Taylor D.R., Zamel N. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010, 138:682-692.
44. Grasemann H., Michler E., Wallot M., Ratjen F. Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr. Pulmonol. 1997, 24:173-177.
45. Grasemann H., Ratjen F. Cystic fibrosis lung disease: the role of nitric oxide. Pediatr. Pulmonol. 1999, 28:442-448.
46. Gaston B., Ratjen F., Vaughan J.W., Malhotra N.R., Canady R.G., Snyder A.H., Hunt J.F., Gaertig S., Goldberg J.B. Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal therapy. Am. J. Respir. Crit. Care Med. 2002, 165:387-390.
47. Grasemann H., Ioannidis I., Tomkiewicz R.P., de Groot H., Rubin B.K., Ratjen F. Nitric oxide metabolites in cystic fibrosis lung disease. Arch. Dis. Child. 1998, 78:49-53.
48. Grasemann H., Schwiertz R., Matthiesen S., Racke K., Ratjen F. Increased arginase activity in cystic fibrosis airways. Am. J. Respir. Crit. Care Med. 2005, 172:1523-1528.
49. Grasemann H., Al-Saleh S., Scott J.A., Shehnaz D., Mehl A., Amin R., Rafii M., Pencharz P., Belik J., Ratjen F. Asymmetric dimethylarginine contributes to airway nitric oxide deficiency in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2011, 183:1363-1368.
50. Grasemann H., Kurtz F., Ratjen F. Inhaled l-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2006, 174:208-212.
51. Grasemann H., Ratjen F. Emerging therapies for cystic fibrosis lung disease. Expert Opin. Emerg. Drugs 2010, 15:653-659.
52. Morrissey B.M., Schilling K., Weil J.V., Silkoff P.E., Rodman D.M. Nitric oxide and protein nitration in the cystic fibrosis airway. Arch. Biochem. Biophys. 2002, 406:33-39.
53. Radi R. Nitric oxide, oxidants, and protein tyrosine nitration. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4003-4008.
54. 2 and inflammatory cytokine production. PLoS One 2008, 3:e3367.
55. Galli F., Piroddi M., Annetti C., Aisa C., Floridi E., Floridi A. Oxidative stress and reactive oxygen species. Contrib. Nephrol. 2005, 149:240-260.
56. Wright D.T., Cohn L.A., Li H., Fischer B., Li C.M., Adler K.B. Interactions of oxygen radicals with airway epithelium. Environ. Health Perspect. 1994, 102(Suppl. 10):85-90.
57. Rahman I., Yang S.R., Biswas S.K. Current concepts of redox signaling in the lungs. Antioxid. Redox Signal. 2006, 8:681-689.
58. 2-mediated activation of NFκB-inducing kinase. J. Biol. Chem. 2006, 281:1495-1505.
59. Boncoeur E., Criq V.S., Bonvin E., Roque T., Henrion-Caude A., Gruenert D.C., Clement A., Jacquot J., Tabary O. Oxidative stress induces extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase in cystic fibrosis lung epithelial cells: potential mechanism for excessive IL-8 expression. Int. J. Biochem. Cell Biol. 2008, 40:432-446.
60. Fischer B., Voynow J. Neutrophil elastase induces MUC5AC messenger RNA expression by an oxidant-dependent mechanism. Chest 2000, 117:317S-320S.
61. Rada B., Gardina P., Myers T.G., Leto T.L. Reactive oxygen species mediate inflammatory cytokine release and EGFR-dependent mucin secretion in airway epithelial cells exposed to Pseudomonas pyocyanin. Mucosal Immunol. 2011, 4:158-171.
62. - transport in human bronchial epithelial cells. Free Radic. Biol. Med. 2008, 45:1653-1662.
63. Hull J., South M., Phelan P., Grimwood K. Surfactant composition in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 1997, 156:161-165.
64. Meyer K.C., Sharma A., Brown R., Weatherly M., Moya F.R., Lewandoski J., Zimmerman J.J. Function and composition of pulmonary surfactant and surfactant-derived fatty acid profiles are altered in young adults with cystic fibrosis. Chest 2000, 118:164-174.
65. Pulfer M.K., Murphy R.C. Formation of biologically active oxysterols during ozonolysis of cholesterol present in lung surfactant. J. Biol. Chem. 2004, 279:26331-26338.
66. Starosta V., Rietschel E., Paul K., Baumann U., Griese M. Oxidative changes of bronchoalveolar proteins in cystic fibrosis. Chest 2006, 129:431-437.
67. Starosta V., Griese M. Oxidative damage to surfactant protein D in pulmonary diseases. Free Radic. Res. 2006, 40:419-425.
68. Griese M., Essl R., Schmidt R., Rietschel E., Ratjen F., Ballmann M., Paul K. Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2004, 170:1000-1005.
69. Griese M., Essl R., Schmidt R., Ballmann M., Paul K., Rietschel E., Ratjen F. Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients. Respir. Res. 2005, 6:133.
70. Wood L.G., Fitzgerald D.A., Gibson P.G., Cooper D.M., Garg M.L. Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients. Am. J. Clin. Nutr. 2002, 75:668-675.
71. Montuschi P., Kharitonov S.A., Ciabattoni G., Corradi M., van Rensen L., Geddes D.M., Hodson M.E., Barnes P.J. Exhaled 8-isoprostane as a new non-invasive biomarker of oxidative stress in cystic fibrosis. Thorax 2000, 55:205-209.
72. Collins C.E., Quaggiotto P., Wood L., O'Loughlin E.V., Henry R.L., Garg M.L. Elevated plasma levels of F2 alpha isoprostane in cystic fibrosis. Lipids 1999, 34:551-556.
73. Hartl D., Starosta V., Maier K., Beck-Speier I., Rebhan C., Becker B.F., Latzin P., Fischer R., Ratjen F., Huber R.M., Rietschel E., Krauss-Etschmann S., Griese M. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs. Free Radic. Biol. Med. 2005, 39:463-472.
74. Milne G.L., Yin H., Morrow J.D. Human biochemistry of the isoprostane pathway. J. Biol. Chem. 2008, 283:15533-15537.
75. Ciabattoni G., Davi G., Collura M., Iapichino L., Pardo F., Ganci A., Romagnoli R., Maclouf J., Patrono C. In vivo lipid peroxidation and platelet activation in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2000, 162:1195-1201.
76. Garenc C., Julien P., Levy E. Oxysterols in biological systems: the gastrointestinal tract, liver, vascular wall and central nervous system. Free Radic. Res. 2011, 44:47-73.
77. Cantin A.M., North S.L., Hubbard R.C., Crystal R.G. Normal alveolar epithelial lining fluid contains high levels of glutathione. J. Appl. Physiol. 1987, 63:152-157.
78. Tirouvanziam R., Conrad C.K., Bottiglieri T., Herzenberg L.A., Moss R.B. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4628-4633.
79. Velsor L.W., Kariya C., Kachadourian R., Day B.J. Mitochondrial oxidative stress in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Respir. Cell Mol. Biol. 2006, 35:579-586.
80. Kelly-Aubert M., Trudel S., Fritsch J., Nguyen-Khoa T., Baudouin-Legros M., Moriceau S., Jeanson L., Djouadi F., Matar C., Conti M., Ollero M., Brouillard F., Edelman A. GSH monoethyl ester rescues mitochondrial defects in cystic fibrosis models. Hum. Mol. Genet. 2011, 20:2745-2759.
81. Ghezzi P. Role of glutathione in immunity and inflammation in the lung. Int. J. Gen. Med. 2011, 4:105-113.
82. Dauletbaev N., Viel K., Buhl R., Wagner T.O., Bargon J. Glutathione and glutathione peroxidase in sputum samples of adult patients with cystic fibrosis. J. Cyst. Fibros. 2004, 3:119-124.
83. Cross C.E., van der Vliet A., O'Neill C.A., Louie S., Halliwell B. Oxidants, antioxidants, and respiratory tract lining fluids. Environ. Health Perspect. 1994, 102(Suppl. 10):185-191.
84. Takeyama K., Dabbagh K., Jeong Shim J., Dao-Pick T., Ueki I.F., Nadel J.A. Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J. Immunol. 2000, 164:1546-1552.
85. Ballatori N., Krance S.M., Notenboom S., Shi S., Tieu K., Hammond C.L. Glutathione dysregulation and the etiology and progression of human diseases. Biol. Chem. 2009, 390:191-214.
86. Soltaninassab S.R., Sekhar K.R., Meredith M.J., Freeman M.L. Multi-faceted regulation of gamma-glutamylcysteine synthetase. J. Cell. Physiol. 2000, 182:163-170.
87. Lopez-Mirabal H.R., Winther J.R. Redox characteristics of the eukaryotic cytosol. Biochim. Biophys. Acta 2008, 1783:629-640.
88. Hwang C., Sinskey A.J., Lodish H.F. Oxidized redox state of glutathione in the endoplasmic reticulum. Science 1992, 257:1496-1502.
89. Murphy M. Mitochondrial thiols in antioxidant protection and redox signalling: distinct roles for glutathionylation and other thiol modifications. Antioxid. Redox Signal. 2011, ahead of print. doi:10.1089/ars.2011.4289.
90. Day B.J., van Heeckeren A.M., Min E., Velsor L.W. Role for cystic fibrosis transmembrane conductance regulator protein in a glutathione response to bronchopulmonary Pseudomonas infection. Infect. Immun. 2004, 72:2045-2051.
91. Zhang Y., Duan K. Glutathione exhibits antibacterial activity and increases tetracycline efficacy against Pseudomonas aeruginosa. Sci. China C Life Sci. 2009, 52:501-505.
92. Hudson V.M. New insights into the pathogenesis of cystic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. Treat. Respir. Med. 2004, 3:353-363.
93. Velsor L.W., van Heeckeren A., Day B.J. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281:L31-L38.
94. Kogan I., Ramjeesingh M., Li C., Kidd J.F., Wang Y., Leslie E.M., Cole S.P., Bear C.E. CFTR directly mediates nucleotide-regulated glutathione flux. EMBO J. 2003, 22:1981-1989.
95. Gould N.S., Gauthier S., Kariya C.T., Min E., Huang J., Brian D.J. Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protective CFTR-dependent thiols against oxidative injury. Respir. Res. 2010, 11:119.
96. Vasu V.T., de Cruz S.J., Houghton J.S., Hayakawa K.A., Morrissey B.M., Cross C.E., Eiserich J.P. Evaluation of thiol-based antioxidant therapeutics in cystic fibrosis sputum: focus on myeloperoxidase. Free Radic. Res. 2011, 45:165-176.
97. Roussel L., Martel G., Berube J., Rousseau S. P. aeruginosa drives CXCL8 synthesis via redundant toll-like receptors and NADPH oxidase in CFTRF508 airway epithelial cells. J. Cyst. Fibros. 2011, 10:107-113.
98. Lau G.W., Hassett D.J., Ran H., Kong F. The role of pyocyanin in Pseudomonas aeruginosa infection. Trends Mol. Med. 2004, 10:599-606.
99. Wilson R., Sykes D.A., Watson D., Rutman A., Taylor G.W., Cole P.J. Measurement of Pseudomonas aeruginosa phenazine pigments in sputum and assessment of their contribution to sputum sol toxicity for respiratory epithelium. Infect. Immun. 1988, 56:2515-2517.
100. Muller M. Pyocyanin induces oxidative stress in human endothelial cells and modulates the glutathione redox cycle. Free Radic. Biol. Med. 2002, 33:1527-1533.
101. O'Malley Y.Q., Reszka K.J., Britigan B.E. Direct oxidation of 2',7'-dichlorodihydrofluorescein by pyocyanin and other redox-active compounds independent of reactive oxygen species production. Free Radic. Biol. Med. 2004, 36:90-100.
102. Caldwell C.C., Chen Y., Goetzmann H.S., Hao Y., Borchers M.T., Hassett D.J., Young L.R., Mavrodi D., Thomashow L., Lau G.W. Pseudomonas aeruginosa exotoxin pyocyanin causes cystic fibrosis airway pathogenesis. Am. J. Pathol. 2009, 175:2473-2488.
103. O'Malley Y.Q., Reszka K.J., Spitz D.R., Denning G.M., Britigan B.E. Pseudomonas aeruginosa pyocyanin directly oxidizes glutathione and decreases its levels in airway epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287:L94-L103.
104. Muller M. Glutathione modulates the toxicity of, but is not a biologically relevant reductant for, the Pseudomonas aeruginosa redox toxin pyocyanin. Free Radic. Biol. Med. 2011, 50:971-977.
105. Cheluvappa R., Shimmon R., Dawson M., Hilmer S.N., Le Couteur D.G. Reactions of Pseudomonas aeruginosa pyocyanin with reduced glutathione. Acta Biochim. Pol. 2008, 55:571-580.
106. Widdicombe J.H. Transgenic animals may help resolve a sticky situation in cystic fibrosis. J. Clin. Invest. 2010, 120:3093-3096.
107. Sun X., Sui H., Fisher J.T., Yan Z., Liu X., Cho H.J., Joo N.S., Zhang Y., Zhou W., Yi Y., Kinyon J.M., Lei-Butters D.C., Griffin M.A., Naumann P., Luo M., Ascher J., Wang K., Frana T., Wine J.J., Meyerholz D.K., Engelhardt J.F. Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J. Clin. Invest. 2010, 120:3149-3160.
108. Joo N.S., Cho H.J., Khansaheb M., Wine J.J. Hyposecretion of fluid from tracheal submucosal glands of CFTR-deficient pigs. J. Clin. Invest. 2010, 120:3161-3166.
109. Bragonzi A. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. IJMM 2010, 300:584-593.
110. van Heeckeren A.M., Schluchter M.D. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab. Anim. 2002, 36:291-312.
111. Bragonzi A., Worlitzsch D., Pier G.B., Timpert P., Ulrich M., Hentzer M., Andersen J.B., Givskov M., Conese M., Doring G. Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J. Infect. Dis. 2005, 192:410-419.
112. G.S., Bedrossian C.W., Singer D.B., Hansen J.J., Rosenberg H.S. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum. Pathol. 1976, 7:195-204.
113. W.D., Cash H.A., McCullough B., Johanson W.G., Bass J.A. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am. Rev. Respir. Dis. 1979, 119:453-459.
114. E.M., Starke J.R., Langston C., Baker C.J. A mouse model of chronic pulmonary infection with Pseudomonas aeruginosa and Pseudomonas cepacia. Pediatr. Res. 1987, 22:698-702.
115. T.J., van Heeckeren A.M., Walenga R.W., Konstan M.W., Davis P.B., Erokwu B., Haxhiu M.A., Ferkol T.W. Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. Am. J. Respir. Crit. Care Med. 2000, 161:271-279.
116. Aw T., Wierzbicka G., Jones D.P. Oral glutathione increases tissue glutathione in vivo. Chem. Biol. Interact. 1991, 80:89-97.
117. Favilli F., Marraccini P., Iantomasi T., Vincenzini M.T. Effect of orally administered glutathione on glutathione levels in some organs of rats: role of specific transporters. Br. J. Nutr. 1997, 78:293-300.
118. Kariya C., Leitner H., Min E., van Heeckeren C., van Heeckeren A., Day B.J. A role for CFTR in the elevation of glutathione levels in the lung by oral glutathione administration. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292:L1590-L1597.
119. Atkuri K., Mantovani J.J., Herzenberg L.A., Herzenberg L.A. N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr. Opin. Pharmacol. 2007, 7:355-359.
120. De Lisle R., Roach E., Jansson K. Effects of laxative and N-acetylcysteine on mucus accumulation, bacterial load, transit, and inflammation in the cystic fibrosis mouse small intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293:G577-G584.
121. A. Luciani, V.R. Villella, S. Esposito, N. Brunetti-Pierri, D. Medina, C. Settembre, M. Gavina, L. Pulze, I. Giardino, M. Pettoello-Mantovani, M. D'Apolito, S. Guido, E. Masliah, B. Spencer, S. Quaratino, V. Raia, A. Ballabio, L. Maiuri, Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition, Nat. Cell Biol. 12 863-875.
122. Griese M., Ramakers J., Krasselt A., Starosta V., Van Koningsbruggen S., Fischer R., Ratjen F., Mullinger B., Huber R.M., Maier K., Rietschel E., Scheuch G. Improvement of alveolar glutathione and lung function but not oxidative state in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2004, 169:822-828.
123. Bishop C., Hudson V.M., Hilton S.C., Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 2005, 127:308-317.
124. Wang W., Oliva C., Li G., Holmgren A., Lillig C.H., Kirk K.L. Reversible silencing of CFTR chloride channels by glutathionylation. J. Gen. Physiol. 2005, 125:127-141.
125. Dauletbaev N., Fischer P., Aulbach B., Gross J., Kusche W., Thyroff-Friesinger U., Wagner T.O., Bargon J. A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. Eur. J. Med. Res. 2009, 14:352-358.
126. Tirouvanziam R., Gernez Y., Conrad C.K., Moss R.B., Schrijver I., Dunn C.E., Davies Z.A., Herzenberg L.A. Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4335-4339.
127. Roum J.H., Borok Z., McElvaney N.G., Grimes G.J., Bokser A.D., Buhl R., Crystal R.G. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J. Appl. Physiol. 1999, 87:438-443.
128. Visca A., Bishop C.T., Hilton S.C., Hudson V.M. Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. J. Cyst. Fibros. 2008, 7:433-436.
129. Nash E.F., Stephenson A., Ratjen F., Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database Syst. Rev. 2009, CD007168.
130. A.C. foundation Drug Development Pipeline 2011.
131. Hoshida S., Kuzuya T., Yamashita N., Nishida M., Kitahara S., Hori M., Kamada T., Tada M. Gamma-glutamylcysteine ethyl ester for myocardial protection in dogs during ischemia and reperfusion. J. Am. Coll. Cardiol. 1994, 24:1391-1397.
132. Lok J., Leung W., Zhao S., Pallast S., van Leyen K., Guo S., Wang X., Yalcin A., Lo E.H. Gamma-glutamylcysteine ethyl ester protects cerebral endothelial cells during injury and decreases blood-brain barrier permeability after experimental brain trauma. J. Neurochem. 2011, 118:248-255.
133. Borok Z., Buhl R., Grimes G.J., Bokser A.D., Hubbard R.C., Holroyd K.J., Roum J.H., Czerski D.B., Cantin A.M., Crystal R.G. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991, 338:215-216.
134. Holroyd K.J., Buhl R., Borok Z., Roum J.H., Bokser A.D., Grimes G.J., Czerski D., Cantin A.M., Crystal R.G. Correction of glutathione deficiency in the lower respiratory tract of HIV seropositive individuals by glutathione aerosol treatment. Thorax 1993, 48:985-989.
135. Hull J., Vervaart P., Grimwood K., Phelan P. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 1997, 52:557-560.
136. Corti A., Paolicchi A., Franzini M., Dominici S., Casini A.F., Pompella A. The S-thiolating activity of membrane gamma-glutamyltransferase: formation of cysteinyl-glycine mixed disulfides with cellular proteins and in the cell microenvironment. Antioxid. Redox Signal. 2005, 7:911-918.
137. Corti A., Franzini M., Casini A.F., Paolicchi A., Pompella A. Vitamin C supply to bronchial epithelial cells linked to glutathione availability in elf-a role for secreted gamma-glutamyltransferase?. J. Cyst. Fibros. 2008, 7:174-178.
138. Munck A. Nutritional considerations in patients with cystic fibrosis. Expert Rev. Respir. Med. 2010, 4:47-56.
139. Matel J.L., Milla C.E. Nutrition in cystic fibrosis. Semin. Respir. Crit. Care Med. 2009, 30:579-586.
140. Salvatore D., Buzzetti R., Baldo E., Forneris M.P., Lucidi V., Manunza D., Marinelli I., Messore B., Neri A.S., Raia V., Furnari M.L., Mastella G. An overview of international literature from cystic fibrosis registries 2. Neonatal screening and nutrition/growth. J. Cyst. Fibros. 2010, 9:75-83.
141. Joosten K.F., Hulst J.M. Malnutrition in pediatric hospital patients: current issues. Nutrition 2011, 27:133-137.
142. Fustik S., Jacovska T., Spirevska L., Koceva S. Protein-energy malnutrition as the first manifestation of cystic fibrosis in infancy. Pediatr. Int. 2009, 51:678-683.
143. Himmelfarb J., McMonagle E. Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int. 2001, 60:358-363.
144. Stenvinkel P., Carrero J.J., Axelsson J., Lindholm B., Heimburger O., Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin. J. Am. Soc. Nephrol. 2008, 3:505-521.
145. Roche M., Rondeau P., Singh N.R., Tarnus E., Bourdon E. The antioxidant properties of serum albumin. FEBS Lett. 2008, 582:1783-1787.
146. Giustarini D., Milzani A., Dalle-Donne I., Rossi R. Red blood cells as a physiological source of glutathione for extracellular fluids. Blood Cells Mol. Dis. 2008, 40:174-179.
147. Meister A., Anderson M.E. Glutathione. Annu. Rev. Biochem. 1983, 52:711-760.
148. Alvarez B., Carballal S., Turell L., Radi R. Formation and reactions of sulfenic acid in human serum albumin. Methods Enzymol. 2010, 473:117-136.
149. Carballal S., Alvarez B., Turell L., Botti H., Freeman B.A., Radi R. Sulfenic acid in human serum albumin. Amino Acids 2007, 32:543-551.
150. Barclay L.R., Bailey A.M., Kong D. The antioxidant activity of alpha-tocopherol-bovine serum albumin complex in micellar and liposome autoxidations. J. Biol. Chem. 1985, 260:15809-15814.
151. Ishii T., Ichikawa T., Minoda K., Kusaka K., Ito S., Suzuki Y., Akagawa M., Mochizuki K., Goda T., Nakayama T. Human serum albumin as an antioxidant in the oxidation of (-)-epigallocatechin gallate: participation of reversible covalent binding for interaction and stabilization. Biosci. Biotechnol. Biochem. 2011, 75:100-106.
152. Galli F., Rovidati S., Benedetti S., Buoncristiani U., Covarelli C., Floridi A., Canestrari F. Overexpression of erythrocyte glutathione S-transferase in uremia and dialysis. Clin. Chem. 1999, 45:1781-1788.
153. Borowitz D., Baker R.D., Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 2002, 35:246-259.
154. Filer L.J., Wright S.W., Manning M.P., Mason K.E. Absorption of alpha-tocopherol and tocopherylesters by premature and full term infants and children in health and disease. Pediatrics 1951, 8:328-339.
155. Lancellotti L., D'Orazio C., Mastella G., Mazzi G., Lippi U. Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation. Eur. J. Pediatr. 1996, 155:281-285.
156. Sathe M.N., Patel A.S. Update in pediatrics: focus on fat-soluble vitamins. Nutr. Clin. Pract. 2010, 25:340-346.
157. Traber M.G. The ABCs of vitamin E and beta-carotene absorption. Am. J. Clin. Nutr. 2004, 80:3-4.
158. Dolan T.F. Hemolytic anemia and edema as the initial signs in infants with cystic fibrosis. Consider this diagnosis even in absence of pulmonary symptoms. Clin. Pediatr. 1976, 15:597-600.
159. James D.R., Alfaham M., Goodchild M.C. Increased susceptibility to peroxide-induced haemolysis with normal vitamin E concentrations in cystic fibrosis. Clin. Chim. Acta 1991, 204:279-290.
160. Peters S.A., Kelly F.J. Vitamin E supplementation in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 1996, 22:341-345.
161. Maqbool A., Stallings V.A. Update on fat-soluble vitamins in cystic fibrosis. Curr. Opin. Pulm. Med. 2008, 14:574-581.
162. Sagel S.D., Sontag M.K., Anthony M.M., Emmett P., Papas K.A. Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis. J. Cyst. Fibros. 2011, 10:31-36.
163. Galli F., Azzi A. Present trends in vitamin E research. Biofactors 2010, 36:33-42.
164. Hamahata A., Enkhbaatar P., Kraft E.R., Lange M., Leonard S.W., Traber M.G., Cox R.A., Schmalstieg F.C., Hawkins H.K., Whorton E.B., Horvath E.M., Szabo C., Traber L.D., Herndon D.N., Traber D.L. Gamma-tocopherol nebulization by a lipid aerosolization device improves pulmonary function in sheep with burn and smoke inhalation injury. Free Radic. Biol. Med. 2008, 45:425-433.
165. Anais J.P., Razzouq N., Carvalho M., Fernandez C., Astier A., Paul M., Astier A., Fessi H., Lorino A.M. Development of alpha-tocopherol acetate nanoparticles: influence of preparative processes. Drug Dev. Ind. Pharm. 2009, 35:216-223.
166. Zingg J.M. Molecular and cellular activities of vitamin E analogues. Mini Rev. Med. Chem. 2007, 7:543-558.
167. Viola V., Pilolli F., Piroddi M., Pierpaoli E., Orlando F., Provinciali M., Betti M., Mazzini F., Galli F. Why tocotrienols work better: insights into the in vitro anti-cancer mechanism of vitamin E. Genes Nutr. 2011, 7:29-41.
168. Galli F., Mazzini F., Bamonti L., Gille L., Bohmdorfer S., Piroddi M., Netscher T., Kelly F.J., Rosenau T. Tocotrienamines and tocopheramines: reactions with radicals and metal ions. Bioorg. Med. Chem. 2011, 19:6483-6491.
169. Kuhad A., Chopra K. Attenuation of diabetic nephropathy by tocotrienol: involvement of NFκB signaling pathway. Life Sci. 2009, 84:296-301.
170. Jiang Q., Yin X., Lill M.A., Danielson M.L., Freiser H., Huang J. Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20464-20469.
171. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142:37-46.
172. Hathcock J.N., Azzi A., Blumberg J., Bray T., Dickinson A., Frei B., Jialal I., Johnston C.S., Kelly F.J., Kraemer K., Packer L., Parthasarathy S., Sies H., Traber M.G. Vitamins E and C are safe across a broad range of intakes. Am. J. Clin. Nutr. 2005, 81:736-745.
173. Brigelius-Flohe R., Galli F. Vitamin E: a vitamin still awaiting the detection of its biological function. Mol. Nutr. Food Res. 2010, 54:583-587.
174. Traber M.G., Frei B., Beckman J.S. Vitamin E revisited: do new data validate benefits for chronic disease prevention?. Curr. Opin. Lipidol. 2008, 19:30-38.
175. Galli F. Meeting report: Vitamin E Satellite Symposium (VESS) associated to the Annual Meeting of the SFRR-Europe, Rome, 26 August, 2009. Free Radic. Res. 2009, 43:1256-1257.
176. Roberts L.J., Oates J.A., Linton M.F., Fazio S., Meador B.P., Gross M.D., Shyr Y., Morrow J.D. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic. Biol. Med. 2007, 43:1388-1393.
177. E.F.S.A.- EFSA, Scientific Opinion of the Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food on a request from the Commission on mixed tocopherols, tocotrienol tocopherol and tocotrienols as sources for vitamin E., in: E.F.S.A.- EFSA (Ed.), vol. 640, The EFSA Journal 2008, pp. 1-34.
178. Rust P., Eichler I., Renner S., Elmadfa I. Long-term oral beta-carotene supplementation in patients with cystic fibrosis - effects on antioxidative status and pulmonary function. Ann. Nutr. Metab. 2000, 44:30-37.
179. Lepage G., Champagne J., Ronco N., Lamarre A., Osberg I., Sokol R.J., Roy C.C. Supplementation with carotenoids corrects increased lipid peroxidation in children with cystic fibrosis. Am. J. Clin. Nutr. 1996, 64:87-93.
180. Winklhofer-Roob B.M., Puhl H., Khoschsorur G., van't Hof M.A., Esterbauer H., Shmerling D.H. Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during beta-carotene supplementation in cystic fibrosis. Free Radic. Biol. Med. 1995, 18:849-859.
181. Graham-Maar R.C., Schall J.I., Stettler N., Zemel B.S., Stallings V.A. Elevated vitamin A intake and serum retinol in preadolescent children with cystic fibrosis. Am. J. Clin. Nutr. 2006, 84:174-182.
182. Sadowska-Woda I., Rachel M., Pazdan J., Bieszczad-Bedrejczuk E., Pawliszak K. Nutritional supplement attenuates selected oxidative stress markers in pediatric patients with cystic fibrosis. Nutr. Res. (New York, N.Y.) 2011, 31:509-518.
183. Papas K.A., Sontag M.K., Pardee C., Sokol R.J., Sagel S.D., Accurso F.J., Wagener J.S. A pilot study on the safety and efficacy of a novel antioxidant rich formulation in patients with cystic fibrosis. J. Cyst. Fibros. 2008, 7:60-67.
184. Saito Y., Fukuhara A., Nishio K., Hayakawa M., Ogawa Y., Sakamoto H., Fujii K., Yoshida Y., Niki E. Characterization of cellular uptake and distribution of coenzyme Q10 and vitamin E in PC12 cells. J. Nutr. Biochem. 2009, 20:350-357.
185. Franke A.A., Morrison C.M., Bakke J.L., Custer L.J., Li X., Cooney R.V. Coenzyme Q10 in human blood: native levels and determinants of oxidation during processing and storage. Free Radic. Biol. Med. 2010, 48:1610-1617.
186. Bhagavan H.N., Chopra R.K. Plasma coenzyme Q10 response to oral ingestion of coenzyme Q10 formulations. Mitochondrion 2007, 7:S78-S88. (Suppl.).
187. Bhagavan H.N., Chopra R.K. Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic. Res. 2006, 40:445-453.
188. Galli F., Lee R., Dunster C., Kelly F.J. Gas chromatography mass spectrometry analysis of carboxyethyl-hydroxychroman metabolites of alpha- and gamma-tocopherol in human plasma. Free Radic. Biol. Med. 2002, 32:333-340.
189. Galli F., Lee R., Atkinson J., Floridi A., Kelly F.J. Gamma-tocopherol biokinetics and transformation in humans. Free Radic. Res. 2003, 37:1225-1233.
190. Laguna T.A., Sontag M.K., Osberg I., Wagener J.S., Accurso F.J., Sokol R.J. Decreased total serum coenzyme-Q10 concentrations: a longitudinal study in children with cystic fibrosis. J. Pediatr. 2008, 153:402-407.
191. Frischer T., Myung J.K., Maurer G., Eichler I., Szepfalusi Z., Lubec G. Possible dysregulation of chaperon and metabolic proteins in cystic fibrosis bronchial tissue. Proteomics 2006, 6:3381-3388.
192. Andersson C., Zaman M.M., Jones A.B., Freedman S.D. Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. J. Cyst. Fibros. 2008, 7:68-78.
193. Freedman S.D., Blanco P.G., Zaman M.M., Shea J.C., Ollero M., Hopper I.K., Weed D.A., Gelrud A., Regan M.M., Laposata M., Alvarez J.G., O'Sullivan B.P. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N. Engl. J. Med. 2004, 350:560-569.
194. Van Biervliet S., Vanbillemont G., Van Biervliet J.P., Declercq D., Robberecht E., Christophe A. Relation between fatty acid composition and clinical status or genotype in cystic fibrosis patients. Ann. Nutr. Metab. 2007, 51:541-549.
195. Freedman S.D., Katz M.H., Parker E.M., Laposata M., Urman M.Y., Alvarez J.G. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13995-14000.
196. Van Biervliet S., Vande Velde S., Van Biervliet J.P., Robberecht E. The effect of zinc supplements in cystic fibrosis patients. Ann. Nutr. Metab. 2008, 52:152-156.
197. Henderson W.R., Astley S.J., McCready M.M., Kushmerick P., Casey S., Becker J.W., Ramsey B.W. Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects. J. Pediatr. 1994, 124:400-408.
198. Durieu I., Vericel E., Guichardant D., Roth H., Steghens J.P., Drai J., Josserand R.N., Fontaine E., Lagarde M., Bellon G. Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: an open pilot observational study. J. Cyst. Fibros. 2007, 6:320-326.
199. Wood L.G., Fitzgerald D.A., Garg M.L. Hypothesis: vitamin E complements polyunsaturated fatty acids in essential fatty acid deficiency in cystic fibrosis. J. Am. Coll. Nutr. 2003, 22:253-257.
200. Lloyd-Still J.D., Johnson S.B., Holman R.T. Essential fatty acid status in cystic fibrosis and the effects of safflower oil supplementation. Am. J. Clin. Nutr. 1981, 34:1-7.
201. Maqbool A., Schall J.I., Garcia-Espana J.F., Zemel B.S., Strandvik B., Stallings V.A. Serum linoleic acid status as a clinical indicator of essential fatty acid status in children with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 2008, 47:635-644.
202. Oliver C., Jahnke N. Omega-3 fatty acids for cystic fibrosis. Cochrane Database Syst. Rev. 2011, CD002201.
203. Strandvik B., Gronowitz E., Enlund F., Martinsson T., Wahlstrom J. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis. J. Pediatr. 2001, 139:650-655.
204. Rise P., Volpi S., Colombo C., Padoan R.F., D'Orazio C., Ghezzi S., Melotti P., Bennato V., Agostoni C., Assael B.M., Galli C. Whole blood fatty acid analysis with micromethod in cystic fibrosis and pulmonary disease. J. Cyst. Fibros. 2010, 9:228-233.
205. Cao H., Gerhold K., Mayers J.R., Wiest M.M., Watkins S.M., Hotamisligil G.S. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 2008, 134:933-944.
206. Malapaka R.R., Khoo S.K., Zhang J., Choi J.H., Zhou X.E., Xu Y., Gong Y., Li J., Yong E.L., Chalmers M.J., Chang L., Resau J.H., Griffin P.R., Chen Y.E., Xu H.E. Identification and mechanism of a ten carbon fatty acid as a modulating ligand of peroxisome proliferator activated receptors. J. Biol. Chem. 2012, 287:183-195.
207. Hara T., Hirasawa A., Ichimura A., Kimura I., Tsujimoto G. Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. J. Pharm. Sci. 2011, 100:3594-3601.
208. Gupta R., Rathi P., Bradoo S. Lipase mediated upgradation of dietary fats and oils. Crit. Rev. Food Sci. Nutr. 2003, 43:635-644.
209. Jennings B.H., Akoh C.C. Lipase-catalyzed modification of rice bran oil to incorporate capric acid. J. Agric. Food Chem. 2000, 48:4439-4443.
210. Hoeks J., Mensink M., Hesselink M.K., Ekroos K., Schrauwen P. Long- and Medium-Chain Fatty Acids Induce Insulin Resistance to a Similar Extent in Humans Despite Marked Differences in Muscle Fat Accumulation. J. Clin. Endocrinol. Metab. 2012, 97:208-216.
211. Congden P.J., Bruce G., Rothburn M.M., Clarke P.C., Littlewood J.M., Kelleher J., Losowsky M.S. Vitamin status in treated patients with cystic fibrosis. Arch. Dis. Child. 1981, 56:708-714.
212. Winklhofer-Roob B.M., Ellemunter H., Fruhwirth M., Schlegel-Haueter S.E., Khoschsorur G., van't Hof M.A., Shmerling D.H. Plasma vitamin C concentrations in patients with cystic fibrosis: evidence of associations with lung inflammation. Am. J. Clin. Nutr. 1997, 65:1858-1866.
213. Shamseer L., Adams D., Brown N., Johnson J.A., Vohra S. Antioxidant micronutrients for lung disease in cystic fibrosis. Cochrane Database Syst. Rev. 2010, CD007020.
214. Santi C., Santoro S. Electrophilic Selenium 2012, Wiley-VCH Verlag GmbH & Co. KGaA. First edition.
215. Flohe L., Toppo S., Cozza G., Ursini F. A comparison of thiol peroxidase mechanisms. Antioxid. Redox Signal. 2010, 15:763-780.
216. Flohe L., Andreesen J.R., Brigelius-Flohe R., Maiorino M., Ursini F. Selenium, the element of the moon, in life on earth. IUBMB Life 2000, 49:411-420.
217. Valdiglesias V., Pasaro E., Mendez J., Laffon B. In vitro evaluation of selenium genotoxic, cytotoxic, and protective effects: a review. Arch. Toxicol. 2010, 84:337-351.
218. Foucaud P., Therond P., Marchand M., Brion F., Demelier J.F., Navarro J. Selenium and vitamin E in mucoviscidosis. Arch. Fr. Pediatr. 1988, 45:383-386.
219. Neve J., Van Geffel R., Hanocq M., Molle L. Plasma and erythrocyte zinc, copper and selenium in cystic fibrosis. Acta Paediatr. Scand. 1983, 72:437-440.
220. Winklhofer-Roob B.M., Tiran B., Tuchschmid P.E., van't Hof M.A., Shmerling D.H. Effects of pancreatic enzyme preparations on erythrocyte glutathione peroxidase activities and plasma selenium concentrations in cystic fibrosis. Free Radic. Biol. Med. 1998, 25:242-249.
221. Lloyd-Still J.D., Ganther H.E. Selenium and glutathione peroxidase levels in cystic fibrosis. Pediatrics 1980, 65:1010-1012.
222. Tsavachidou D., McDonnell T.J., Wen S., Wang X., Vakar-Lopez F., Pisters L.L., Pettaway C.A., Wood C.G., Do K.A., Thall P.F., Stephens C., Efstathiou E., Taylor R., Menter D.G., Troncoso P., Lippman S.M., Logothetis C.J., Kim J. Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J. Natl. Cancer Inst. 2009, 101:306-320.
223. Zelko I.N., Mariani T.J., Folz R.J. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic. Biol. Med. 2002, 33:337-349.
224. Bowler R.P., Crapo J.D. Oxidative stress in airways: is there a role for extracellular superoxide dismutase?. Am. J. Respir. Crit. Care Med. 2002, 166:S38-S43.
225. Best K., McCoy K., Gemma S., Disilvestro R.A. Copper enzyme activities in cystic fibrosis before and after copper supplementation plus or minus zinc. Metabolism 2004, 53:37-41.
226. Percival S.S., Kauwell G.P., Bowser E., Wagner M. Altered copper status in adult men with cystic fibrosis. J. Am. Coll. Nutr. 1999, 18:614-619.
227. Krebs N.F., Westcott J.E., Arnold T.D., Kluger B.M., Accurso F.J., Miller L.V., Hambidge K.M. Abnormalities in zinc homeostasis in young infants with cystic fibrosis. Pediatr. Res. 2000, 48:256-261.
228. Easley D., Krebs N., Jefferson M., Miller L., Erskine J., Accurso F., Hambidge K.M. Effect of pancreatic enzymes on zinc absorption in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 1998, 26:136-139.
229. Van Biervliet S., Van Biervliet J.P., Robberecht E. Serum zinc in patients with cystic fibrosis at diagnosis and after one year of therapy. Biol. Trace Elem. Res. 2006, 112:205-211.
230. Van Biervliet S., Van Biervliet J.P., Vande Velde S., Robberecht E. Serum zinc concentrations in cystic fibrosis patients aged above 4years: a cross-sectional evaluation. Biol. Trace Elem. Res. 2007, 119:19-26.
231. Galli F., Cristina Polidori M., Stahl W., Mecocci P., Kelly F.J. Vitamin E biotransformation in humans. Vitam. Horm. 2007, 76:263-280.
232. Wiser J., Alexis N.E., Jiang Q., Wu W., Robinette C., Roubey R., Peden D.B. In vivo gamma-tocopherol supplementation decreases systemic oxidative stress and cytokine responses of human monocytes in normal and asthmatic subjects. Free Radic. Biol. Med. 2008, 45:40-49.
233. Wagner J.G., Jiang Q., Harkema J.R., Illek B., Patel D.D., Ames B.N., Peden D.B. Ozone enhancement of lower airway allergic inflammation is prevented by gamma-tocopherol. Free Radic. Biol. Med. 2007, 43:1176-1188.
234. Harries J.T., Muller D.P. Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Arch. Dis. Child. 1971, 46:341-344.
235. Back E.I., Frindt C., Ocenaskova E., Nohr D., Stern M., Biesalski H.K. Can changes in hydrophobicity increase the bioavailability of alpha-tocopherol?. Eur. J. Nutr. 2006, 45:1-6.
236. Nasr S.Z., O'Leary M.H., Hillermeier C. Correction of vitamin E deficiency with fat-soluble versus water-miscible preparations of vitamin E in patients with cystic fibrosis. J. Pediatr. 1993, 122:810-812.
237. Soltani-Frisk S., Gronowitz E., Andersson H., Strandvik B. Water-miscible tocopherol is not superior to fat-soluble preparation for vitamin E absorption in cystic fibrosis. Acta Paediatr. 2001, 90:1112-1115.
238. Papas K., Kalbfleisch J., Mohon R. Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients. Dig. Dis. Sci. 2007, 52:347-352.
239. Antonicelli F., Parmentier M., Drost E.M., Hirani N., Rahman I., Donaldson K., MacNee W. Nacystelyn inhibits oxidant-mediated interleukin-8 expression and NF-kappaB nuclear binding in alveolar epithelial cells. Free Radic. Biol. Med. 2002, 32:492-502.
240. App E.M., Baran D., Dab I., Malfroot A., Coffiner M., Vanderbist F., King M. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. Eur. Respir. J. 2002, 19:294-302.
241. Traber M.G. How much vitamin E? Just enough!. Am. J. Clin. Nutr. 2006, 84:959-960.
242. McCann J.C., Ames B.N. Vitamin K, an example of triage theory: is micronutrient inadequacy linked to diseases of aging?. Am. J. Clin. Nutr. 2009, 90:889-907.
243. Fusaro M., Crepaldi G., Maggi S., Galli F., D'Angelo A., Calo L., Giannini S., Miozzo D., Gallieni M. Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: an important but poorly studied relationship. J. Endocrinol. Invest. 2010, 34:317-323.
244. McCann J.C., Ames B.N. Adaptive dysfunction of selenoproteins from the perspective of the triage theory: why modest selenium deficiency may increase risk of diseases of aging. FASEB J. 2011, 25:1793-1814.
245. Apak R., Guclu K., Ozyurek M., Bektas Oglu B., Bener M. Cupric ion reducing antioxidant capacity assay for food antioxidants: vitamins, polyphenolics, and flavonoids in food extracts. Methods Mol. Biol. 2008, 477:163-193.
246. Galli F. Interactions of polyphenolic compounds with drug disposition and metabolism. Curr. Drug Metab. 2007, 8:830-838.
247. Prior R.L., Wu X., Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J. Agric. Food Chem. 2005, 53:4290-4302.
248. Azbell C., Zhang S., Skinner D., Fortenberry J., Sorscher E.J., Woodworth B.A. Hesperidin stimulates cystic fibrosis transmembrane conductance regulator-mediated chloride secretion and ciliary beat frequency in sinonasal epithelium. Otolaryngol. Head Neck Surg. 2010, 143:397-404.
249. Wegrzyn G., Jakobkiewicz-Banecka J., Gabig-Ciminska M., Piotrowska E., Narajczyk M., Kloska A., Malinowska M., Dziedzic D., Golebiewska I., Moskot M., Wegrzyn A. Genistein: a natural isoflavone with a potential for treatment of genetic diseases. Biochem. Soc. Trans. 2010, 38:695-701.
250. Yu Y.C., Miki H., Nakamura Y., Hanyuda A., Matsuzaki Y., Abe Y., Yasui M., Tanaka K., Hwang T.C., Bompadre S.G., Sohma Y. Curcumin and genistein additively potentiate G551D-CFTR. J. Cyst. Fibros 2011, 10:243-252.
251. Illek B., Fischer H. Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am. J. Physiol. 1998, 275:L902-L910.
252. Kreindler J.L. Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. Pharmacol. Ther. 2010, 125:219-229.
253. Illek B., Zhang L., Lewis N.C., Moss R.B., Dong J.Y., Fischer H. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am. J. Physiol. 1999, 277:C833-C839.
254. Anandakumar P., Kamaraj S., Jagan S., Ramakrishnan G., Vinodhkumar R., Devaki T. Capsaicin modulates pulmonary antioxidant defense system during benzo(a)pyrene-induced lung cancer in Swiss albino mice. Phytother. Res. 2008, 22:529-533.
255. Rahman I. Antioxidant therapeutic advances in COPD. Ther. Adv. Respir. Dis. 2008, 2:351-374.
256. Boots A.W., Li H., Schins R.P., Duffin R., Heemskerk J.W., Bast A., Haenen G.R. The quercetin paradox. Toxicol. Appl. Pharmacol. 2007, 222:89-96.
257. Joskova M., Franova S., Sadlonova V. Acute bronchodilator effect of quercetin in experimental allergic asthma. Bratisl. Lek. Listy 2011, 112:9-12.
258. Park H.J., Lee C.M., Jung I.D., Lee J.S., Jeong Y.I., Chang J.H., Chun S.H., Kim M.J., Choi I.W., Ahn S.C., Shin Y.K., Yeom S.R., Park Y.M. Quercetin regulates Th1/Th2 balance in a murine model of asthma. Int. Immunopharmacol. 2009, 9:261-267.
259. Rogerio A.P., Kanashiro A., Fontanari C., da Silva E.V., Lucisano-Valim Y.M., Soares E.G., Faccioli L.H. Anti-inflammatory activity of quercetin and isoquercitrin in experimental murine allergic asthma. Inflamm. Res. 2007, 56:402-408.
260. Muller M. Polyphenol cytotoxicity induced by the bacterial toxin pyocyanin: role of NQO1. Free Radic. Biol. Med. 2009, 47:84-91.
261. Grassmann J. Terpenoids as plant antioxidants. Vitam. Horm. 2005, 72:505-535.
262. Allen P. Tea tree oil: the science behind the antimicrobial hype. Lancet 2001, 358:1245.
263. Dasenbrook E.C., Checkley W., Merlo C.A., Konstan M.W., Lechtzin N., Boyle M.P. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010, 303:2386-2392.
264. Bezzerri V., Borgatti M., Nicolis E., Lampronti I., Dechecchi M.C., Mancini I., Rizzotti P., Gambari R., Cabrini G. Transcription factor oligodeoxynucleotides to NF-kappaB inhibit transcription of IL-8 in bronchial cells. Am. J. Respir. Cell Mol. Biol. 2008, 39:86-96.
265. Gambari R., Borgatti M., Bezzerri V., Nicolis E., Lampronti I., Dechecchi M.C., Mancini I., Tamanini A., Cabrini G. Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA chimeras targeting nuclear factor kappa-B: inhibition of IL-8 gene expression in cystic fibrosis cells infected with Pseudomonas aeruginosa. Biochem. Pharmacol. 2010, 80:1887-1894.
266. Adrian M., Jeandet P., Douillet-Breuil A.C., Tesson L., Bessis R. Stilbene content of mature Vitis vinifera berries in response to UV-C elicitation. J. Agric. Food Chem. 2000, 48:6103-6105.
267. Paul B., Masih I., Deopujari J., Charpentier C. Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. J. Ethnopharmacol. 1999, 68:71-76.
268. Rahman I. Antioxidant therapies in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2006, 1:15-29.
269. Lee M., Kim S., Kwon O.K., Oh S.R., Lee H.K., Ahn K. Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int. Immunopharmacol. 2009, 9:418-424.
270. Wood L.G., Wark P.A., Garg M.L. Antioxidant and anti-inflammatory effects of resveratrol in airway disease. Antioxid. Redox Signal. 2010, 13:1535-1548.
271. Kiselev K.V. Perspectives for production and application of resveratrol. Appl. Microbiol. Biotechnol. 2011, 90:417-425.
272. Shakibaei M., Buhrmann C., Mobasheri A. Resveratrol-mediated SIRT-1 interactions with p300 modulate receptor activator of NF-kappaB ligand (RANKL) activation of NF-kappaB signaling and inhibit osteoclastogenesis in bone-derived cells. J. Biol. Chem. 2011, 286:11492-11505.
273. Zaidi S.F., Ahmed K., Yamamoto T., Kondo T., Usmanghani K., Kadowaki M., Sugiyama T. Effect of resveratrol on Helicobacter pylori-induced interleukin-8 secretion, reactive oxygen species generation and morphological changes in human gastric epithelial cells. Biol. Pharm. Bull. 2009, 32:1931-1935.
274. Kundu J.K., Shin Y.K., Surh Y.J. Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets. Biochem. Pharmacol. 2006, 72:1506-1515.
275. Nam N.H. Naturally occurring NF-kappaB inhibitors. Mini Rev. Med. Chem. 2006, 6:945-951.
276. Smoliga J.M., Baur J.A., Hausenblas H.A. Resveratrol and health-a comprehensive review of human clinical trials. Mol. Nutr. Food Res. 2011, 55:1129-1141.
277. Juan M.E., Maijo M., Planas J.M. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J. Pharm. Biomed. Anal. 2010, 51:391-398.
278. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. 2006, 5:493-506.
279. Nicolis E., Lampronti I., Dechecchi M.C., Borgatti M., Tamanini A., Bianchi N., Bezzerri V., Mancini I., Giri M.G., Rizzotti P., Gambari R., Cabrini G. Pyrogallol, an active compound from the medicinal plant Emblica officinalis, regulates expression of pro-inflammatory genes in bronchial epithelial cells. Int. Immunopharmacol. 2008, 8:1672-1680.
280. Nicolis E., Lampronti I., Dechecchi M.C., Borgatti M., Tamanini A., Bezzerri V., Bianchi N., Mazzon M., Mancini I., Giri M.G., Rizzotti P., Gambari R., Cabrini G. Modulation of expression of IL-8 gene in bronchial epithelial cells by 5-methoxypsoralen. Int. Immunopharmacol. 2009, 9:1411-1422.
281. Borgatti M., Mancini I., Bianchi N., Guerrini A., Lampronti I., Rossi D., Sacchetti G., Gambari R. Bergamot (Citrus bergamia Risso) fruit extracts and identified components alter expression of interleukin 8 gene in cystic fibrosis bronchial epithelial cell lines. BMC Biochem. 2011, 12:15.
282. Piccagli L., Fabbri E., Borgatti M., Bianchi N., Bezzerri V., Mancini I., Nicolis E., Dechecchi C.M., Lampronti I., Cabrini G., Gambari R. Virtual screening against p50 NF-kappaB transcription factor for the identification of inhibitors of the NF-kappaB-DNA interaction and expression of NF-kappaB upregulated genes. ChemMedChem 2009, 4:2024-2033.
283. Piccagli L., Borgatti M., Nicolis E., Bianchi N., Mancini I., Lampronti I., Vevaldi D., Dall'Acqua F., Cabrini G., Gambari R. Virtual screening against nuclear factor kappaB (NF-kappaB) of a focus library: identification of bioactive furocoumarin derivatives inhibiting NF-kappaB dependent biological functions involved in cystic fibrosis. Bioorg. Med. Chem. 2010, 18:8341-8349.
284. Borgatti M., Chilin A., Piccagli L., Lampronti I., Bianchi N., Mancini I., Marzaro G., Francesco D.a., Guiotto A., Gambari R. Development of a novel furocoumarin derivative inhibiting NF-kappaB dependent biological functions: design, synthesis and biological effects. Eur. J. Med. Chem. 2011, 46:4870-4877.
285. Georgy E., Le Guellec S., Vecellio L., Fichant E., Stordeur P., Bordeau P., Perraudin J.P. Feasibility study of OSCN- and lactoferrin (Meveol) nebulization for cystic fibrosis. J. Cyst. Fibros 2011, 10:S18.
286. Tidei C., Piroddi M., Galli F., Santi C. Oxidation of thiols promoted by PhSeZnCl. Tetrahedron Lett. 2012, 53:232-234.
287. Semianrio-Vidal L., van Hesuden C., Mugesh G., Lazarowski E.R. Ebselen is a potent non-competitive inhibitor of extracellular nucleoside diphosphokinase. Purinergic Signal. 2010, 6:383-391.
288. 2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells from apoptosis. FASEB J. 2000, 14:2266-2276.
289. Xiao H., Parkin K.L. Induction of phase II enzyme activity by various selenium compounds. Nutr. Cancer 2006, 55:210-223.
290. Peluffo G., Radi R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc. Res. 2007, 75:291-302.
291. Alvarez B., Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003, 25:295-311.
292. Kamosinska B., Radomski M.W., Duszyk M., Radomski A., Man S.F. Nitric oxide activates chloride currents in human lung epithelial cells. Am. J. Physiol. 1997, 272:L1098-L1104.
293. Chen L., Patel R.P., Teng X., Bosworth C.A., Lancaster J.R., Matalon S. Mechanisms of cystic fibrosis transmembrane conductance regulator activation by S-nitrosoglutathione. J. Biol. Chem. 2006, 281:9190-9199.
294. Luchetti F., Canonico B., Betti M., Arcangeletti M., Pilolli F., Piroddi M., Canesi L., Papa S., Galli F. Melatonin signaling and cell protection function. FASEB J. 2010, 24:3603-3624.
295. Bengtsson M.W., Jedstedt G., Flemstrom G. Duodenal bicarbonate secretion in rats: stimulation by intra-arterial and luminal guanylin and uroguanylin. Acta Physiol. (Oxf.) 2007, 191:309-317.
296. Nelson C.S., Marino J.L., Allen C.N. Melatonin receptor potentiation of cyclic AMP and the cystic fibrosis transmembrane conductance regulator ion channel. J. Pineal Res. 1999, 26:113-121.
297. de Castro-Silva C., de Bruin V.M., Cunha G.M., Nunes D.M., Medeiros C.A., de Bruin P.F. Melatonin improves sleep and reduces nitrite in the exhaled breath condensate in cystic fibrosis-a randomized, double-blind placebo-controlled study. J. Pineal Res. 2010, 48:65-71.
298. Hornyak I., Pankotai E., Kiss L., Lacza Z. Current developments in the therapeutic potential of S-nitrosoglutathione, an endogenous NO-donor molecule. Curr. Pharm. Biotechnol. 2011, Jan 11. [Epub ahead of print] - PMID: 21235457.
299. Snyder A.H., McPherson M.E., Hunt J.F., Johnson M., Stamler J.S., Gaston B. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2002, 165:922-926.